ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2487

In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare

Antonella Adinolfi1, Giovanni Cagnotto2, Filippo Luccioli3, Claudio Mastaglio4, Giulia Mirabelli3, Daniela Rossi5, Silvia Rossi2, Emanuela Bellis6, Greta Carrara7, Carlo Alberto Scirè8, Annamaria Iagnocco9 and Garifallia Sakellariou2, 1Policlinico le Scotte, Siena, Italy, 2University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, 3University of Perugia, Perugia, Italy, 4Moriggia-Pelascini, Gravedona, Italy, 5Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, 6Rheumatology, Ospedale Mauriziano, Turin, Italy, 7Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 8Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, 9Sapienza University of Rome, Rome, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: prognostic factors, remission, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Ultrasound (US) detected synovitis predicts flare in patients with rheumatoid arthritis (RA), while the role of tenosynovitis has yet to be established. The aim of this study was to investigate the predictive role of US tenosynovitis and synovitis over disease flare in patients with RA in clinical remission in which treatment is tapered.

Methods:

STARTER is a multicentre cohort study of the US Study Group of the Italian Society for Rheumatology, involving rheumatologists selected by a reliability exercise and the availability of high-end equipment and high frequencies probes. At the beginning of the study, patients with RA in clinical remission were clinically evaluated. US synovitis (S) and tenosynovitis (T) were assessed categorically for Grey Scale (GS) and power Doppler (PD) at 11 joints, extensor and flexor tendons in both hands. Patients were seen at 6 and 12 months. Treatment tapering was defined as dose reduction or discontinuation of any DMARD or corticosteroids. Flare within 12 months was defined as increase in DAS28 ≥1.2 or ≥0.6 if final DAS28>3.2. The relationship between the presence of GS-T/-S, PD-T/-S and flare was tested by logistic regression models, presented as odds ratios (OR) and 95% confidence interval (CI), adjusted for pre-specified confounders (age, sex, disease duration, comorbidities, rheumatoid factor, synthetic or biologic DMARDs, corticosteroids or NSAIDs). The models were applied to the whole population and separately in subgroups of patients in which treatment was or was not reduced.

Results:

361 patients were included, in 161 treatment was tapered [72. % F, mean age (sd) 56.1 (13.3) years, mean disease duration (sd) 9.75 (8.07) years]. 98/361 patients  had a flare within 12 months, 48/154 among those tapering treatment. Considering US variables separately, only PD-S significantly predicted flare both in the whole population and in patients tapering treatment, but not in patients on stable treatment. When the model included both T and S, only the concurrent presence of T and S predicted flare [PD-T+-S: OR 2.06(1.04, 4.07)] in the overall population, while isolated S and T did not. The predictive value of PD-T+-S was not confirmed in patients in stable treatment, while it was enhanced in patients tapering treatment [OR 3.16(1.18,8.45)]. In the whole population GS-T+GS-S led to an increased risk of flare [OR 2.27, (1.01,5.10)], but this was not confirmed in the subgroups (Table 1).

Conclusion:

In patients with RA in clinical remission PD-T and PD-S predict subsequent disease flare, especially if treatment is tapered down. In addition to clinical evaluation, US could provide helpful information to drive treatment strategies in patients in clinical remission.

 

US abnormality

Overall population

Stable treatment

Tapering treatment

Crude OR (95% CI)

Adj OR (95%CI)

Crude OR (95% CI)

Adj OR (95%CI)

Crude OR (95% CI)

Adj OR (95%CI)

GS-T

1.59 (0.53,4.72)

1.53 (0.47,4.92)

1.87 (0.47,7.36)

1.73 (0.34,7.77)

1.22 (0.18,7.89)

1.40 (0.18,10.50)

GS-S

2.18 (0.97,4.92)

1.93 (0.81,4.57)

2.0 (0.65,6.10)

1.77 (0.50,6.19)

2.37 (0.70,8.02)

2.22 (0.61,8.02)

GS-T+-S

2.88 (1.34,6.14)

2.27 (1.01,5.10)

2.29 (0.84,6.22)

1.64 (0.53,5.01)

3.76 (1.16,12.20)

3.42 (0.98,11.92)

PD-T

0.59 (0.16,2.15)

0.47 (0.12,1.79)

0.34 (0.04,2.86)

0.34 (0.03,3.04)

1.31 (0.23,7.41)

0.82 (0.12,5.42)

PD-S

1.64 (0.93,2.90)

1.56 (0.85,2.85)

1.78 (0.80,3.95)

1.48 (0.61,3.58)

1.54 (0.68,3.50)

1.56 (0.64,3.76)

PD-T+-S

2.75 (1.45,5.20)

2.06 (1.04,4.07)

2.31 (0.95,5.64)

1.58 (0.58,4.32)

3.54 (1.40,8.98)

3.16 (1.18,8.45)

Table 1. Logistic regression models analyzing the predictive role of US findings over disease flare. OR: Odds Ratio, 95% CI: 95% confidence interval; GS: grey scale; PD: power Doppler; T: tenosynovitis; S: synovitis


Disclosure: A. Adinolfi, None; G. Cagnotto, None; F. Luccioli, None; C. Mastaglio, None; G. Mirabelli, None; D. Rossi, None; S. Rossi, None; E. Bellis, None; G. Carrara, None; C. A. Scirè, None; A. Iagnocco, None; G. Sakellariou, None.

To cite this abstract in AMA style:

Adinolfi A, Cagnotto G, Luccioli F, Mastaglio C, Mirabelli G, Rossi D, Rossi S, Bellis E, Carrara G, Scirè CA, Iagnocco A, Sakellariou G. In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/in-patients-with-rheumatoid-arthritis-in-clinical-remission-undergoing-treatment-tapering-tenosynovitis-and-synovitis-detected-by-ultrasonography-predict-disease-flare/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-patients-with-rheumatoid-arthritis-in-clinical-remission-undergoing-treatment-tapering-tenosynovitis-and-synovitis-detected-by-ultrasonography-predict-disease-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology